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Introduction: Acute respiratory distress syndrome (ARDS) is a major cause of mortality in intensive care units.
Patients with ARDS often require parenteral nutrition with lipid emulsions as essential components. Besides being
an energy supply, these lipid emulsions might display differential modulatory effects on lung integrity and
inflammation.
Methods: In a pre-emptive strategy, we investigated the impact of three different intravenously infused lipid
emulsions on lung morphology, leukocyte invasion, protein leakage and cytokines in a murine model of ARDS.
Mice received an infusion of normal saline solution, a pure long-chain triglycerides (LCT) emulsion, a medium-chain
triglycerides (MCT) containing mixed emulsion (LCT/MCT), or a fish oil (FO) containing mixed emulsion
(LCT/MCT/FO) before lipopolysaccharide (LPS) challenge.
Results: Mice pre-infused with fish oil-containing lipid emulsion showed decreased leukocyte invasion, protein
leakage, myeloperoxidase activity, and cytokine production in their alveolar space after LPS challenge compared to
mice receiving LCT or LCT/MCT. In line with these findings, lung morphology assessed by histological staining after
LPS-induced lung injury improved faster in the LCT/MCT/FO group. Concerning the above mentioned parameters,
no significant difference was observed between mice infused with LCT or the combination of LCT and MCT.
Conclusion: Fish oil-containing lipid emulsions might exert anti-inflammatory and pro-resolving effects in the
murine model of acute lung injury. Partial replacement of n-6 fatty acids with n-3 fatty acids may thus be of
benefit for critically ill patients at risk for ARDS which require parenteral nutrition.Introduction
Acute respiratory distress syndrome (ARDS) is a common
clinical disorder characterized by alveolar epithelial and
endothelial injuries leading to the development of protein-
rich non-cardiogenic pulmonary edema, elevation of pul-
monary artery pressure and, finally, respiratory failure [1].
The incidence of ARDS was 4.5 to 7.1% in all patients
admitted to an intensive care unit (ICU) [2,3]. This per-
centage increases to 12.5% when considering only patients* Correspondence: Konstantin.Mayer@uglc.de
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reproduction in any medium, provided the ortreated longer than 24 h in the ICU [3]. Despite a mul-
titude of promising pharmacological approaches being
successful in animal studies, there is at present no proven
pharmaceutical option available for ARDS patients. This is
reflected by the still unacceptable high mortality rate of 30
to 40% [4]. The pathophysiology of ARDS is complex and
still not fully understood. The acute phase of ARDS is
characterized by a widespread disruption of the alveolar-
capillary barrier leading to increased vascular permeability,
neutrophil invasion into the interstitial and alveolar space,
and the formation of pro-inflammatory mediators such as
cytokines and eicosanoids [1,4].
Lipid emulsions are considered as essential components
of clinical parenteral nutrition regimens applied to criticallyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Fatty acid composition (g/L) of the lipid emulsions
used assessed by gas chromatography
Fatty acid LCT LCT/MCT LCT/MCT/FO
8:0 0.00 57.21 55.42
10:0 0.00 41.78 41.45
16:0 21.56 10.27 10.57
16:1 0.00 0.00 0.21
18:0 11.20 7.67 7.43
18:1 49.52 26.85 24.09
18:2 106.07 48.57 41.20
18:3 11.47 6.05 4.49
20:4 0.18 0.40 0.76
20:5 0.00 0.00 5.12
22:5 0.00 0.00 1.60
22:6 0.00 0.19 4.54
Hecker et al. Critical Care 2014, 18:R85 Page 2 of 11
http://ccforum.com/content/18/2/R85ill patients. Besides providing adequate caloric support,
several studies indicate the immunomodulatory properties
of lipid emulsions, as shown by their ability to alter cyto-
kine release, to modify leukocyte function, and to influence
the generation of lipid mediators that display both
pro- and anti-inflammatory properties [5-7]. For a long
time supplementation of fatty acids was exclusively relying
on soybean or safflower oil-based long-chain triglycerides
(LCT), which contain a large amount of linoleic acid
(LOA, 18:2), a n-6 polyunsaturated fatty acid (PUFA),
serving as a precursor of arachidonic acid (AA). Rapid and
extended infusion of such lipid emulsions may thus
increase the plasma concentration of free arachidonic acid
by one order of magnitude, leading to a modulation of the
eicosanoid profile, deterioration of the oxygenation index
and alteration of the ventilation-perfusion matching of the
lung. The combination of LCT with medium-chain trigly-
cerides (MCT) in a 1:1 ratio was introduced into nutrition
regimes as MCT were cleared rapidly from the serum,
and displayed less adverse liver outcomes and reduced the
provision of n-6 PUFA by 50% [8-10]. The administration
of n-3 PUFA, as fish oil (FO), offers a novel promising
strategy to enrich nutrition regimes as it has been shown
to modulate excessive inflammatory reactions in ani-
mals, healthy volunteers and subjects in clinical trials
[11]. Nevertheless, the clinical use of n-3 PUFA in ARDS
patients is at present debated. In critically ill patients
suffering from sepsis or ARDS, enteral supplementation of
n-3-based lipid emulsions reduced mortality and displayed
anti-inflammatory properties [5]. On the other hand, a
large multi-center study, conducted by the ARDSnet, was
recently published and investigatedg the effects of an
enteral supplementation of n-3 fatty acids in ARDS pa-
tients [12]. The study was stopped early because of futility;
it displayed a higher rate of complications in the group
receiving n-3 fatty acids. Due to the inconsistency of data
concerning the enteral use of n-3 fatty acids in ARDS,
there is an on-going debate in the scientific community
with no final recommendation available at the moment.
Despite our better understanding of the pathophysio-
logical effects caused by the currently available lipid emul-
sions in clinical use for parenteral nutrition, especially the
value of novel emulsions, such as mixed lipid emulsions
containing MCT/LCT and/or FO, their use in ARDS
requires further investigation. Due to the novelty of these
lipid emulsions in clinical use there is still a paucity of data
in experimental models and clinical settings.
In the present study, we investigate the effects of
conventional LCT-based lipid emulsions in the murine
model of endotoxin-induced ARDS compared to mixtures
of MCT/LCT with or without FO supplementation. For
this purpose, we make use of a continuous long-term lipid
infusion system, followed by endotoxin challenge and
subsequent in vivo and in vitro analyses. For our study, wechose a “pre-emptive” strategy by administration of lipid
emulsions prior to induction of lung injury. The back-
ground of this concept is the choice of an appropriate lipid
emulsion for patients in need of parenteral nutrition and
with an expected trauma/operation or at risk, for example,
of aspiration-induced respiratory distress.
Materials and methods
Reagents
A soybean-based lipid emulsion (LCT; Lipoven 20%®) was
purchased from Fresenius-Kabi (Bad Homburg, Germany).
Both the mixtures of LCT (50%) and MCT (50%) (LCT/
MCT; Lipofundin 20%®) and LCT (40%)/MCT(50%)/FO
(10%) (Lipoplus 20%®) were obtained from B.Braun
(Melsungen, Germany). Analysis of the fatty acid com-
position of the lipid emulsions is given in Table 1. Chemi-
cals of the highest purity were obtained from Merck
(Darmstadt, Germany). Lipopolysaccharides (LPS, O111:
B4) from E. coli were obtained from Sigma-Aldrich
(Dreisenhofen, Germany).
Animals and experimental protocol
All animal experiments were performed in Giessen;
animal experiments were approved by the animal pro-
tection branch of the Regierungspräsident Gießen and
the animal protection representative of the University of
Giessen. BALB/c mice were kept under standard con-
ditions with a 12 hour day: night cycle under specific
pathogen-free conditions. Animals 13 to 15 weeks old
(22 to 24 g in weight) were used for the experiments. The
implantation of a jugular vein catheter and subsequent
adaptation to an osmotic mini-pump (Alzet, Cupertino,
CA, USA) was performed as described previously [13].
Seven days after central venous catheter implantation
in mice, an exchange of pumps was performed. Then,
either 200 μl per day of LCT, LCT/MCT, LCT/MCT/FO
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with the mice being allowed access to water and chow
ad libitum. The amount of lipids infused is equivalent to
1.5 g/kg/d. However, the energy expenditure of mice is
nearly three times higher than that in humans. There-
fore, the infused lipids were considered to be close to
the lower limits of the recommended amount of lipids in
parenteral nutrition. While receiving infusions, mice were
subjected to low dose unfractionated heparin injected
subcutaneously.
LPS-induced acute lung injury in a murine model
After completion of the infusion regimen, mice were
anesthetized with xylazine/ketamine, a small catheter was
inserted in the trachea, and LPS (0 or 10 μg in 200 μl
normal saline/mouse) was instilled by using a Micro-
sprayer (Penn-Century Inc., Philadelphia, PA, USA). A
total of 4, 24 or 48 hours after LPS-application, mice were
anesthetized as described before and volumetric computed
tomography of the lung was performed. After that, mice
were sacrificed with an overdose of anesthesia (xylazine/
ketamine), and their lungs were either taken for further
examination or a bronchoalveolar lavage (BAL) was per-
formed as described previously [14].
Assessment of lung edema
Lung edema was estimated by protein determination in
BAV according to Lowry [15].
Histological assessment of lung morphology
For histochemical assessment of lung morphology, tissue
was fixed, embedded and stained with hematoxylin and
eosin as previously described [16].
Volumetric computer tomography
Mice were anesthetized and examined by high-resolution
flat-panel volumetric computed tomography (fpvCT). This
CT is exclusively used for experimental trials in animals.
Examinations are acquired at 120 kV and 40 mA. One
thousand projection images are taken within one gantry
rotation of eight seconds duration. A matrix of 1,024
columns × 360 rows is the read-out of the flat-panel
detector. Images are reconstructed using a cone-beam
filtered back-projection algorithm with an isotropic voxel
size of 0.05 mm.
BAL leukocytes counts
Mice were killed by an overdose of anesthesia, and
BAL was performed in situ as described [14]. Alveolar-
recruited leukocytes recovered from the lungs of LPS-
challenged and control mice were counted in a counting
chamber under a light microscope. Differential leukocyte
counting analysis was performed after H&E staining.Enzyme-linked immunosorbent assay (ELISA)
Tumor-necrosis factor (TNF)-α, macrophage inflamma-
tory protein (MIP)-2, prostaglandin (PG)E2 (all purchased
from R&D Systems, Wiesbaden, Germany), and thromb-
oxane (Tx)B2 (Assay Designs, Ann Arbor, MI, USA) from
BAL were determined by ELISA, according to the manu-
facturers’ instructions.
Myeloperoxidase assay
Lung myeloperoxidase (MPO) was determined as an index
of tissue neutrophil accumulation after LPS challenge as
previously described [13]. After weighing the lungs stored
at -80°C, the frozen lungs were homogenized, sonicated
and centrifuged at 25,000 × g. MPO activity was calculated
from the change in absorbance (460 nm) resulting from
decomposition of H2O2 in the presence of o-dianisidine.
Determination of free fatty acids in plasma
Plasma was collected directly after sacrifice by venous
puncture and free fatty acids were determined by gas
chromatography as described [17].
Statistics
Data are given as the mean±SEM. Independent experiments
(n = 6 to 8) were performed per group and time-point. Two-
way analysis of variance (ANOVA) was performed to test for
differences between different infusion groups. Post-hoc analysis
was carried out using Student-Newman-Keuls test. Probability
(P) values <0.05 were considered to indicate statistical
significance. Analysis was carried out using SigmaStat® 3.5
for Windows (Systat Software GmbH; Erkrath, Germany).
Results
Effects of lipid emulsions on lung morphology and
inflammation after induction of ARDS
Mice were infused with NaCl, LCT, LCT/MCT or LCT/
MCT/FO over three days, followed by intra-tracheal
application of LPS 24 h prior to being sacrificed. Lung
morphology was assessed by histology to evaluate the in-
flammatory effect. Before challenge, lungs of mice from
all treatment groups displayed a similar histological
pattern (Figure 1A). After LPS instillation, lungs of ani-
mals infused with NaCl showed a marked increase in
leukocyte invasion into the alveolar space and interstitial
edema as signs of pulmonary inflammation and damage.
These morphological features of acute lung injury were
even more pronounced in the LCT and LCT/MCT
group. In contrast, leukocyte invasion and edema forma-
tion were ameliorated in mice receiving LCT/MCT/FO.
In a second approach, lung morphology and the extent
of lung injury was assessed by high-resolution flat-panel
volumetric computed tomography (Figure 1B). Inde-
pendent of the lipid infusions applied, none of the lungs
showed pathologies such as relevant pleural effusions,
Figure 1 Morphological effects of lipid emulsions after induction of ARDS. A. Histological assessment of lung morphology before (0 h) and
24 h after LPS-induced ARDS. B. Representative example of high-resolution flat-panel volumetric computed tomography of lungs before (left) and
24 h after induction of ARDS (right). ARDS, acute respiratory distress syndrome; LPS, lipopolysaccharide.
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injury.
Effect of lipid emulsions on alveolar recruitment of
leukocytes in LPS-induced acute respiratory distress
syndrome
Mice were infused for three days with normal saline
solution (NaCl control), LCT, LCT/MCT or LCT/MCT/
FO, respectively, followed by intra-tracheal application
of 10 μg LPS, and the performance of a BAL 4 hours, 24
hours or 48 hours later. Without LPS-challenge, we
found 0.10 ± 0.03 × 106 leukocytes in BAL fluid without
significant variation between the NaCl and lipid infusion
groups (Figure 2A). After stimulation with LPS, leukocytes
migrated into the alveolar space with their numbers in
BAL fluid rising to 0.70 ± 0.16 × 106 cells (*, P <0.05 vs.
control) after 4 h, to 2.75 ± 0.25 × 106 24 h after LPS instil-
lation (*, P <0.05 vs. control), and to 2.62 ± 0.71 × 106 after
48 h of stimulation (*, P <0.05 vs. control). The same
significant effects were observed for the different lipid
emulsions 4 h, 24 h and 48 h after induction of ARDS
compared to control (**, LCT; ***, LCT/MCT; § LCT/
MCT/FO). For all lipids and NaCl the leukocyte counts
were significantly different between the time-points exceptcomparing 24 h and 48 h. After 24 h of LPS-stimulation
the LCT group displayed an increased amount of alveolar
leukocytes compared to the NaCl group ($, P <0.05). For
the other time-points, both LCT- and LCT/MCT-infused
animals showed no significant difference on LPS-induced
leukocyte invasion as compared to the NaCl group. Mice
receiving LCT/MCT/FO infusions displayed the lowest
number of alveolar leukocytes at all time-points after LPS
stimulation in comparison to control animals and mice
receiving the other lipid emulsions (%, P <0.05). Next, we
performed a differential cell count of BAL leukocytes to
elucidate the percentage of lymphocytes, monocytes/mac-
rophages (M/M) and neutrophils (PMN). In the NaCl
group, LPS instillation induced a dramatic decline in M/
M, whereas relative PMN amount strongly increased and
lymphocytes remained unchanged. Interestingly, this cel-
lular pattern was valid for all different time-points. The
differential leukocyte count in the BAL of mice treated
with the different lipid emulsions showed no significant
difference compared to NaCl (Figure 2B).
Accumulation of neutrophils in lung tissue
MPO activity was measured before and 24 h and 48 h
after LPS-challenge in all groups to assess neutrophil
Figure 2 Invasion of leukocytes into the alveolar space in LPS-induced ARDS. A. In ARDS, leukocytes migrated into the alveolar space in all
groups (*, NaCl; **, LCT; ***, LCT/MCT; § LCT/MCT/FO). After 24 h of LPS-stimulation the LCT group displayed an increased number of leukocytes
compared to the NaCl group ($). Mice receiving LCT/MCT/FO infusions displayed the lowest number of alveolar leukocytes at all time-points after
LPS stimulation compared to all other groups (%). B. The percentage of lymphocytes, monocytes/macrophages (M/M) and polymononuclear cells
(PMN) was calculated in the BAL of all treatment groups and time-points. The time course for the NaCl group is shown but the same pattern was
detectable for all other groups. C. Myeloperoxidase (MPO) activity as a marker of PMN invasion increased significantly after 24 h and 48 h in the
NaCl group (*) and all other groups compared to control (**, LCT; ***, LCT/MCT; § LCT/MCT/FO). A total of 24 h after ARDS, the LCT group
displayed the highest MPO activity of all groups ($). After 48 h, MPO activity was the lowest in animals receiving LCT/MCT/FO as compared to all
other groups (%). D. In all groups a significant increase in protein extravasation 4 h, 24 h and 48 h after induction of ARDS could be observed,
which was valid for NaCl (*) and the other groups (**, LCT; ***, LCT/MCT; § LCT/MCT/FO). After 48 h of LPS challenge, the mice receiving LCT/
MCT/FO showed significantly reduced levels of protein leakage as compared to NaCl-, LCT-, and LCT/MCT-infused mice at this time-point (%).
Data are given as mean ± SEM (n = 6 to 8 independent experiments each). All markers indicate P <0.05. ARDS, acute respiratory distress
syndrome; BAL, bronchoalveolar lavage; FO, fish oil; LCT, pure long-chain triglycerides; LPS, lipopolysaccharide; MCT, medium-chain triglycerides;
MPO, myeloperoxidase.
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LPS exposure, MPO activity did not differ significantly
among the different treatment groups (Figure 2C). After
instillation of 10 μg LPS, MPO activity increased signifi-
cantly to 15.9 ± 0.7 units/g after 24 h and to 37.0 ± 1.4
units/g after 48 h in the NaCl group (*, P <0.05). The
same significant effects were observed for the different
lipid emulsions 24 h and 48 h after induction of ARDS
compared to control (**, LCT; ***, LCT/MCT; § LCT/
MCT/FO). A total of 24 h after ARDS, the LCT
group displayed the highest MPO activity of all groups
($, P <0.05). After 48 h, MPO activity was the lowest
in animals receiving LCT/MCT/FO as compared to NaCl
and the other treatment groups (%, P <0.05).
LPS-induced protein extravasation in ARDS
Baseline protein concentrations in the BAL fluids showed
no significant differences among the different treatment
regimes (Figure 2D). Compared to these values we could
observe a significant increase in protein extravasation in
all respective groups 4 h, 24 h and 48 h after induction of
ARDS, which was valid for NaCl (*, P <0.05) and the
different lipid emulsions (**, LCT; ***, LCT/MCT; § LCT/MCT/FO). A total of 48 h after LPS challenge, mice
receiving LCT/MCT/FO showed significantly reduced
levels of protein leakage as compared to NaCl-, LCT- and
LCT/MCT-infused mice at this time-point (%, P <0.05).
Cytokine and lipid mediator generation in ARDS
Next, we assessed the influence of the different lipid
emulsions on the generation of several pro-inflammatory
cytokines after the onset of ARDS. The concentration of
TNF-α in BAL was determined at 72 pg/ml ± 11 pg/ml
under baseline conditions in the NaCl group; comparable
levels were detected in animals receiving the different lipid
emulsions (Figure 3A). For all treatment groups (*, NaCl,**,
LCT; ***, LCT/MCT; § LCT/MCT/FO; P <0.05), we could
measure a significant increase of TNF-α concentrations 4 h
after ARDS induction (4,716 ± 499 pg/ml; NaCl), followed
by a steady decrease at 24 h (303 ± 50 pg/ml; NaCl) and
48 h (218 ± 25 pg/ml; NaCl) after LPS-stimulation. After
24 h of injury, mice receiving LCT/MCT/FO showed
significantly reduced TNF-α levels as compared to NaCl
and LCT ($, P <0.05). Furthermore, at 48 h after ARDS
induction, the highest TNF-α concentrations at that time
point were found in the NaCl group (%, P <0.05).
Figure 3 Effect of lipid emulsions on mediators in the BAL after LPS-induced ARDS. A. For all treatment groups (*, NaCl; **, LCT; ***,
LCT/MCT; §, LCT/MCT/FO), TNF-α concentrations were increased 4 h after ARDS induction. After 24 h of injury, the LCT/MCT/FO group showed
reduced levels as compared to NaCl and LCT ($). The highest concentrations were found in the NaCl group 48 h after ARDS induction (%).
B. Highest MIP-2 concentrations in the NaCl group were measured 4 h after LPS application (*). Under basal conditions, LCT (**) and LCT/MCT
(***) displayed elevated levels compared to NaCl. The highest values were measured after 4 h in all groups (§). Animals infused with LCT/MCT/FO
displayed the lowest MIP-2 levels at 24 h compared to the other groups ($). After 48 h, the highest concentrations were detectable for NaCl in
comparison to LCT and LCT/MCT/FO (%). C. A significant increase of TxB2 in the NaCl group was observed after 24 h compared to baseline (*).
After 24 h and 48 h, TxB2 was rising in the LCT- (**) and LCT/MCT-group (**) compared to baseline. After 24 h, reduced levels were detected
in the LCT/MCT/FO group as compared to LCT and LCT/MCT ($). After 48 h the highest concentrations were measured in animals receiving
LCT/MCT compared to NaCl and LCT/MCT/FO (%). D. PGE2 values were elevated in all treatment groups compared to 0 h and 4 h (*). Mice
treated with LCT/MCT/FO showed significantly reduced PGE2 concentration after 48 h as compared to NaCl and LCT ($). Data are given as mean
± SEM (n = 6 to 8 independent experiments each). All markers are P <0.05. ARDS, acute respiratory distress syndrome; FO, fish oil; LCT, pure
long-chain triglycerides; LPS, lipopolysaccharide; MCT, medium-chain triglycerides; MIP-2, macrophage inflammatory protein; PGE2, prostaglandin
E2; TNF-α, tumor necrosis factor alpha; TxB2, thromboxane B2.
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BAL (Figure 3B). Starting with comparable basal concen-
trations in all groups (64 ± 10 pg/ml; NaCl), a peak was
reached 4 h after LPS application (3,338 ± 501 pg/ml;
NaCl), followed by a steady decline to baseline concentra-
tions after 24 h (161 ± 11 pg/ml; NaCl) and 48 h (117 ± 22
pg/ml; NaCl) (*, P <0.05). Interestingly, under basal con-
ditions, LCT (**, P <0.05) and LCT/MCT (***, P <0.05)
displayed significantly elevated MIP-2 levels compared to
NaCl. Highest MIP-2 values were measured after 4 h in all
groups (§, P <0.05). In line with previous results, animals
infused with LCT/MCT/FO displayed the lowest MIP-2
levels 24 h after induction of ARDS compared to the other
groups ($, P <0.05). After 48 h, highest MIP-2 concentra-
tions were detectable for NaCl in comparison to LCT and
LCT/MCT/FO (%, P <0.05).
Under baseline conditions, thromboxane (Tx)B2 con-
centration in BAL fluid was 31 ± 5 pg/ml withoutsignificant differences irrespective of the infused lipid
emulsions (Figure 3C). Similar results could be observed 4
h (35 ± 3 pg/ml; NaCl) after LPS stimulation. A significant
increase of TxB2 in the NaCl group was only observed
after 24 h compared to baseline (*, P <0.05). A total of 24
h and 48 h after induction of ARDS, TxB2 was increasing
significantly in the LCT (**, P <0.05) and LCT/MCT (***.
P <0.05) groups compared to baseline conditions. After 24
h we could detect significantly reduced TxB2 levels in the
LCT/MCT/FO group as compared to the LCT and LCT/
MCT groups ($, P <0.05). After 48 h, the highest TxB2
concentrations were measured in animals receiving LCT/
MCT compared to NaCl and LCT/MCT/FO (%, P <0.05).
Prostaglandin (PG)E2 displayed comparable concentra-
tions 0 h (33 ± 6 pg/ml; NaCl) and 4 h (15 ± 1 pg/ml; NaCl)
after induction of ARDS with comparable levels in all group
(Figure 3D). PGE2 values after 24 h (371 ± 155 pg/ml;
NaCl) and 48 h (213 ± 39 pg/ml; NaCl) were significantly
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(*, P <0.05). Mice treated with LCT/MCT/FO showed a
significantly reduced PGE2 concentration 48 h after induc-
tion of ARDS as compared to NaCl and LCT ($, P <0.05).
Analysis of fatty acids in plasma
In order to study the effect of the different lipid emul-
sions under conditions of ARDS on the composition of
plasma free fatty acids, plasma concentrations of eico-
sapentaenoic acid (EPA, 20:5), docosahexaenoic acid
(DHA, 22:6), linoleic acid (LOA, 18:2), arachidonic acid
(AA, 20:4) and oleic acid (OA, 18:1) were determined by
gas chromatography.
Mice receiving LCT/MCT/FO displayed significantly
elevated EPA levels 4 h after LPS stimulation as compared
to NaCl, LCT and LCT/MCT (*, P <0.05) and to EPA levels
at other time points ($, P <0.05) (Figure 4A). Interestingly,
EPA concentrations in the NaCl group were the lowest 4 hFigure 4 Free fatty acids in plasma after infusion of lipid emulsions in
significantly elevated EPA levels 4 h after LPS stimulation as compared to N
points ($, P <0.05). EPA concentrations in the NaCl group were the lowest
after 24 h the highest compared to all time points (%, P <0.05). B. A total o
in the LCT/MCT/FO group (*, P <0.05) compared to all time points and to a
the NaCl group (§, P <0.05) and LCT/MCT group (%, P <0.05) could be dete
significantly higher LOA levels at baseline compared to NaCl and LCT/MCT/FO
LCT were the highest compared to the other treatment groups (**, P <0.05). D
infused with LCT were significantly higher than in the LCT/MCT/FO group ($,
concentrations as compared to NaCl, LCT/MCT and LCT/MCT/FO (*, P <0.05).
each). AA, arachidonic acid; ARDS, acute respiratory distress syndrome; DHA, d
long-chain triglycerides; LOA, linoleic acid; LPS, lipopolysaccharide; MCT, mediafter induction of ARDS compared to 0 h and 24 h
(§, P <0.05) and the highest after 24 h compared to all
time points (%, P <0.05). Similar results could be observed
for DHA. Four hours after induction of ARDS, we could
measure the highest DHA levels within the LCT/MCT/FO
group (*, P <0.05) compared to all time points and to ani-
mals receiving LCTand LCT/MCT ($, P <0.05) (Figure 4B).
Furthermore, the highest DHA levels in the NaCl group (§,
P <0.05) and LCT/MCT group (%, P <0.05) could be
detected after 4 h of LPS stimulation. Concerning the n-6
fatty acids LOA and AA, similar kinetics could be detected
as concentrations peaked for all treatment groups 4 h after
LPS application. Mice infused with LCT had significantly
higher LOA levels at baseline compared to NaCl and LCT/
MCT/FO (*, P <0.05) (Figure 4C). After 4 h and 24 h, LOA
concentrations in mice receiving LCT were the highest
compared to the other treatment groups (**, P <0.05). A
total of 24 h after LPS challenge, AA concentrations inexperimental ARDS. A. Mice receiving LCT/MCT/FO displayed
aCl, LCT and LCT/MCT (*, P <0.05) and to EPA levels at other time
4 h after induction of ARDS compared 0 h and 24 h (§, P <0.05) and
f 4 h after induction of ARDS, the highest DHA levels were measured
nimals receiving LCT and LCT/MCT ($, P <0.05). Highest DHA levels in
cted after 4 h of LPS stimulation. C. Mice infused with LCT had
(*, P <0.05) After 4 h and 24 h, LOA concentrations in mice receiving
. A total of 24 h after LPS challenge, AA concentrations in animals
P <0.05). E. After 4 h, LCT-infused mice had significantly elevated OA
Data are given as mean ± SEM (n = 6 to 8 independent experiments
ocosahexaenoic acid; EPA, eicosapentaenoic acid; FO, fish oil; LCT, pure
um-chain triglycerides; OA, oleic acid.
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the LCT/MCT/FO group ($, P <0.05) (Figure 4D). LOA
and AA plasma levels in mice receiving LCT/MCT and
LCT/MCT/FO were comparable in all groups. Further-
more, the n-9 fatty acid OA displayed highest levels 4 h
after LPS application in all groups (Figure 4E). After 4 h,
LCT-infused mice had significantly elevated OA concentra-
tions as compared to NaCl, LCT/MCT and LCT/MCT/FO
(*, P <0.05).
Discussion
In the present study we investigated the impact of three
different commercially available lipid emulsions in a murine
model of acute respiratory distress syndrome. We were
able to demonstrate that mice treated with a novel lipid
emulsion containing LCT/MCT/FO displayed reduced
pulmonary leukocyte invasion, protein leakage and cyto-
kine generation compared to animals receiving LCT or
LCT/MCT. Furthermore, it became evident that the
combination of the LCT and MCT showed no benefit
compared to LCT in LPS-induced lung injury despite our
observation of reduced levels of the n-6 fatty acids linoleic
acid and arachidonic acid in the plasma of mice receiving
LCT/MCT.
A striking finding of our study is the clear immuno-
modulatory effect of FO-containing lipid emulsions on
the development and progression of a LPS-induced acute
lung injury. Several biological mechanisms may have con-
tributed to this beneficial effect of FO. Increased provision
of n-3 fatty acids (Fas), EPA and DHA, as mirrored in the
plasma, may result in augmented incorporation of these
FAs into the cell membrane phospholipids and thereby
partially replace AA [7,18]. Of note, the highest DHA
concentrations were found in the NaCl group at 4 h after
ARDS-induction, resembling a feature found in wild type
and fat-1 mice [17]. Instead, EPA concentrations were
increased in the LCT/MCT/FO group at this time point.
It is open to speculation whether infusion of lipids inter-
fered with the generation of free DHA in the course of
injury in the groups receiving lipid emulsions and how
provision of LCT/MCT/FO increased availability of re-
leasable EPA. On the other hand, AA-derived eicosanoids,
such as TxB2 and PGE2, are generated to a lesser extent in
mice receiving n-3 rich FO compared to LCT and LCT/
MCT. Besides alterations in eicosanoid synthesis, n-3-
induced changes in membrane composition interfered
with phospholipid-derived second messengers involved in
cell signal transduction, such as formation of inositol-
phosphates [19], phosphatidylinositol 3-kinase-dependent
signaling [20] or activation of protein kinase C [21].
Camandola and colleagues were able to demonstrate that
n-6 FAs, unlike EPA, stimulate nuclear translocation and
subsequent activation of the transcription factor NF-κB, a
key mediator of inflammatory processes [22]. The findingof reduced levels of TNF-α and MIP-2, the murine equiva-
lent of IL-8, in the BAL fluid of LCT/MCT/FO-treated
mice in our study can be thus explained by the above-
mentioned pathomechanisms.
In our study, intrapulmonary invasion of leukocytes as
a characteristic feature of ARDS was reduced in mice
receiving FO-containing lipid emulsions, whereas LCT
or LCT/MCT increased pulmonary recruitment of neu-
trophils and lung injury. This finding is strengthened by
the observation of reduced MPO activity in lung tissue
of FO-treated mice after induction of ARDS. The differ-
ential effect of n-3 FA transmigration of neutrophils
through the endothelial-epithelial barrier is complex and
only partly understood. The n-3 lipids may regulate this
multistep process via a reduced presentation of endothe-
lial adhesion molecules [23,24] and the attenuation of
the rolling of monocytes [25,26].
Besides the aforementioned properties of n-3 FA in the
context of inflammation and ARDS, the recent discovery
of novel EPA- and DHA-derived lipid mediators called
resolvins represents a milestone in this field of research as
these molecules have been found to play a major role in
repair and resolution of inflammation [27-29]. A potential
impact of resolvins on ARDS remains thus far speculative
as the detection of resolvins in BAL fluid in the model of
LPS-induced lung injury is difficult to achieve [17].
Direct comparison between the LCT and LCT/MCT
results of our study may contribute to the on-going
controversial debate on the immunological role of MCT
in inflammation. The rationale for implementation of
MCT-based lipid emulsions in nutrition regimes are their
biochemical properties allowing easy accessibility for
metabolic degradation and rapid transport into cells with-
out transport systems [7,10,30]. With respect to the influ-
ence of MCT on the immune system, published data have
failed to produce a uniform picture. In the experimental
setting, LCT/MCT and MCT increase monocyte adhesion
and degranulation [31,32], whereas another study reported
decreased neutrophil capacity to kill fungal pathogens
[33]. The few existing clinical studies demonstrate on the
one hand a beneficial effect of LCT/MCT on the de-
velopment of abscesses after laparotomy [34] but on
the other hand aggravated tissue inflammation in patients
with ARDS [35]. The data of our present study suggest a
similar effect of LCT compared to LCT/MCT in many
respects. Our results emphasize the hypothesis that the in-
fluence of lipid emulsions on immunological or biological
functions are at least in part determined by their n-6
to n-3 ratio which is identical between LCT (7:1) and
LCT/MCT (7:1).
Although this is the first report of continuous infusion
of LCT/MCT/FO in murine ARDS, our observations are
consistent with previous experimental and clinical stud-
ies. Recently, our group demonstrated that fat-1 mice,
Hecker et al. Critical Care 2014, 18:R85 Page 9 of 11
http://ccforum.com/content/18/2/R85which possess the ability to endogenously convert n-6 to
n-3 FA and thus exhibit high levels of EPA/DHA, display
reduced features of ARDS and inflammation as com-
pared to wild-type mice [17]. Heller and colleagues con-
ducted a database analysis in 661 intensive care patients
with a major fraction suffering from abdominal sepsis
[5]. The authors could demonstrate that supplementa-
tion of FO into a parenteral nutrition regime exhibits a
dose-dependent reduction in length of stay on an ICU
and antibiotic demand. Furthermore, in patients receiv-
ing FO (0.15 to 0.25 g/kg/d) mortality was decreased
significantly [5]. Although the study was neither controlled
nor randomized, these findings demonstrated a clinical
benefit from the incorporation of FO in parenteral nutri-
tion regimes of critically ill patients. Further evidence for
the positive effects of FO was recently provided by a
randomized controlled study applying FO-containing lipid
emulsions to 40 patients with acute severe pancreatitis
[36]. Patients in the n-3 group displayed improved CRP
levels and oxygenation indices compared to patients
treated with standard lipid emulsions. One of the most re-
cent clinical trials evaluated the effect of a FO-containing
lipid emulsion on the immunological and clinical outcome
of septic patients [37]. Inclusion of FO in parenteral nutri-
tion provided to septic patients led to altered inflamma-
tory cytokine concentrations and improved gas exchange,
whereas the length of stay on the ICU and mortality did
not differ among the different groups [37].
It is intriguing that thus far no clinical data have been
published on the impact of parenterally applied FO-
containing lipid emulsions on the clinical outcome of
ARDS. The lack of valid studies in the field of parenteral
nutrition in ARDS reinforces the on-going debate on an
optimal lipid supply to these patients.
Unlike the parenteral use of n-3 fatty acids in acute lung
injury, the enteral application of FO-containing lipids is
more fully evaluated thus far. The first multi-centered,
controlled and randomized study by Gadek and colleagues
investigated the effect of enteral FO-containing immu-
nonutrition on the clinical outcome of 146 patients with
ARDS [38]. Patients receiving FO in combination with
some other active components showed a significantly
improved oxygenation and reduced recruitment of neu-
trophils in the BAL. Also, non-pulmonary parameters as
length of stay on ICU or incidence of new organ failures
were improved in the FO-treatment group. In line with
these findings, further clinical trials with patients suffering
from ARDS [18] and sepsis [11,39] could demonstrate the
beneficial effect of n-3 fatty acids partly supplemented
with gamma-linolenic acid on oxygenation, duration of
mechanical ventilation and organ function. However, the
published trials evaluated only patients with continuous
full enteral feeding and used a control diet high in n-6
lipids. In contrast, the results of the OMEGA trialconducted by the ARDSnet, posed a challenge [12]. This
large phase III trial testing the effect of bolus application
of n-3 fatty acids and immuno-supplements in ARDS was
stopped due to lack of efficiency and a higher rate of
complications in the group of ARDS patients receiving
n-3 fatty acids. The supplementation of higher amounts
of proteins in the control group and bolus application of
n-3 fatty acids leading to possible changes in bioavailabil-
ity were a matter of debate [40]. In line with the findings
of the OMEGA trial, Stapleton and colleagues also could
not find a beneficial effect of enterally applied FO on
pulmonary and systemic inflammation on patients with
ARDS [41].
In conclusion, the use of n-3 fatty acids, especially in
patients with acute lung injury, still bears uncertainties
due to a lack of studies. Future investigations are needed,
focusing on the mode of application (enteral vs. paren-
teral/bolus vs. continuous), the identification of an optimal
dose of n-3 fatty acids, and the best time-point for starting
n-3-based nutrition regimes.
In spite of the limitation of our study as to the use of
the LPS-induced model of ARDS, which is evidently
different from clinical and experimental ARDS induced
by bacterial infections, our data clearly demonstrate the
beneficial effects of n-3 fatty acids applied parenterally
in murine ARDS.
Conclusion
Fish-oil containing lipid emulsions exert anti-inflammatory
and pro-resolving effects in the murine model of LPS-
induced ARDS. Thus, prophylactic integration of n-3 fatty
acids into a nutritional regime of patients expecting a
trauma/operation might be beneficial in reducing pulmon-
ary inflammatory complications.
Key messages
 Lipid emulsions commercially available for
parenteral application exert different immunological
effects in a murine model of LPS-induced ARDS.
 Lipid-emulsions rich in n-6 fatty acids appear to
increase alveolar recruitment of leukocytes and
accumulation of neutrophils in lung tissue after
LPS-challenge.
 Fish-oil containing lipid emulsions display
anti-inflammatory and pro-resolving properties
after LPS stimulation.
 No significant difference was observed between mice
infused with LCT or with the combination of LCT
and MCT.
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